ACD/Labs’ 200 Employees Join Revvity’s Life Sciences Segment

Introduction

Revvity’s acquisition of Advanced Chemistry Development, Inc. (ACD/Labs) has brought approximately 200 employees into Revvity’s Life Sciences segment, strengthening the company’s capabilities in scientific software, research informatics, analytical characterization, and molecular design.

The acquisition, completed during the first quarter of fiscal 2026, was valued at $72 million in cash at closing, with up to an additional $8 million in contingent consideration based on revenue-related milestones through 2028. Revvity has confirmed that ACD/Labs’ operations are now reported within its Life Sciences segment.

ACD/Labs Brings 200-Strong Scientific Software Team

Based in Toronto, Canada, ACD/Labs is a provider of scientific software solutions supporting analytical characterization and molecular design across pharmaceutical and materials science markets.

The company brings approximately 200 employees to Revvity, adding specialized expertise in chemical informatics, analytical science, molecular design, and research software.

The addition of this workforce is strategically important because scientific software requires both technology expertise and a deep understanding of laboratory and research workflows. ACD/Labs’ team has experience developing solutions that support scientists across different stages of research and development.

Strengthening Revvity’s Life Sciences Business

The integration of ACD/Labs expands Revvity’s Life Sciences capabilities beyond traditional laboratory and research technologies into a broader scientific software and informatics ecosystem.

ACD/Labs’ technologies support areas such as analytical data management, spectral analysis, molecular property prediction, and chemical research workflows. These capabilities complement Revvity’s existing Signals software portfolio.

Revvity initially announced the acquisition as a way to expand the breadth and depth of Revvity Signals and strengthen its ability to connect analytical data with actionable scientific insights.

Supporting Pharmaceutical and Materials Science Research

The acquisition is particularly relevant to pharmaceutical and materials science companies, where researchers increasingly depend on software to manage complex scientific information.

Modern laboratories generate large amounts of data from analytical instruments, experiments, molecular models, and research workflows. Bringing these data sources together can help scientists search, analyze, interpret, and reuse information more efficiently.

ACD/Labs’ expertise in analytical characterization and molecular design therefore gives Revvity an opportunity to provide more connected solutions to customers operating across research, development, and manufacturing environments.

A Strategic Addition to Revvity Signals

One of the key benefits of bringing ACD/Labs into Revvity is the potential to strengthen Revvity Signals, the company’s scientific software platform.

The combination of Revvity Signals with ACD/Labs’ scientific software portfolio can help bridge different stages of the research process—from molecular design and analytical characterization to broader development and manufacturing workflows.

This supports the industry's wider movement toward integrated research informatics, where organizations seek to connect experimental data, analytical results, and scientific decision-making through unified digital platforms.

Acquisition Financials

Revvity paid $72 million in cash at closing for ACD/Labs and could pay up to another $8 million in contingent consideration depending on the achievement of specified revenue metrics through 2028.

The acquisition also included identifiable intangible assets, including developed technology, customer relationships, trade names and trademarks, and backlog. Revvity recorded approximately $32 million in goodwill associated with the acquisition.

These figures indicate that the transaction was a focused investment aimed at expanding Revvity’s scientific software capabilities while adding ACD/Labs’ established technology and specialized workforce.

What the Employee Integration Means

The addition of approximately 200 ACD/Labs employees gives Revvity access to an experienced team already familiar with the needs of pharmaceutical, chemical, and materials science customers.

Rather than simply acquiring software assets, Revvity is also integrating the expertise behind those technologies into its Life Sciences organization. This can support continued product development, customer support, software integration, and innovation.

For ACD/Labs employees, joining Revvity also places their expertise within a larger global life sciences organization, potentially providing additional resources and opportunities to expand the reach of their technologies.

Impact on the Scientific Software Market

The integration highlights the increasing importance of scientific software within the broader life sciences industry.

As pharmaceutical and chemical companies accelerate digital transformation, demand is growing for platforms that can manage scientific data and support researchers throughout the product-development lifecycle.

The acquisition positions Revvity to compete more strongly in this market by combining its existing Life Sciences portfolio with ACD/Labs’ specialized chemical and analytical software capabilities.

Conclusion

The integration of approximately 200 ACD/Labs employees into Revvity’s Life Sciences segment represents an important component of Revvity’s acquisition strategy.

By combining ACD/Labs’ scientific software expertise with Revvity’s global Life Sciences business and Signals software platform, the company is expanding its capabilities in analytical characterization, molecular design, and research informatics.

As scientific organizations continue to generate increasingly complex datasets and demand more connected digital workflows, the combined expertise of Revvity and ACD/Labs could help deliver more integrated solutions for pharmaceutical, biotechnology, chemical, and materials science research.